Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 18, 2022

BUY
$16.98 - $25.54 $6,384 - $9,603
376 New
376 $1.53 Million
Q2 2022

Jul 12, 2022

SELL
$13.15 - $20.45 $4,944 - $7,689
-376 Closed
0 $0
Q3 2021

Oct 12, 2021

BUY
$26.01 - $38.22 $9,779 - $14,370
376 New
376 $12,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $270M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Koshinski Asset Management, Inc. Portfolio

Follow Koshinski Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Koshinski Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Koshinski Asset Management, Inc. with notifications on news.